Intranasal Dexmedetomidine on Blood Pressure in Elderly Hypertensive Patients Undergoing Cataract Surgery

PHASE3RecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
CataractHypertension
Interventions
DRUG

Intranasal dexmedetomidine

Intranasal dexmedetomidine (1 mcg/kg ideal body weight) will be diluted to a total volume of 1 ml and will be administered via a mucosal atomization device (MAD) 30 minutes before surgery. The dose will be divided evenly, with 0.5 mL sprayed into each nostril while the patient is in a semi-recumbent position.

DRUG

Intranasal normal saline

Intranasal normal saline (1 ml) will be administered via mucosal atomization device (MAD) 30 minutes before surgery. The dose will be divided evenly, with 0.5 mL sprayed into each nostril while the patient is in a semi-recumbent position.

Trial Locations (1)

41522

RECRUITING

Suez Canal University Hospitals, Ismailia

All Listed Sponsors
lead

Suez Canal University

OTHER